The scale of the clinical problem justifies the effort. PMADs carry consequences not only for the affected parent but also for child development, family functioning, and long-term health outcomes. What makes the perinatal window scientifically fascinating is that it coincides with two of the most dramatic physiological events in adult life: profound hormonal fluctuations and large-scale brain plasticity. Estrogen and progesterone rise to concentrations far exceeding any other period of adult physiology, then plummet after delivery, while the brain undergoes measurable remodeling across gray matter, white matter, and functional networks. The missing piece is a mechanistic account of how these neurobiological changes translate into psychiatric symptoms, and the PMADS project is engineered to supply exactly that.

The study design is deliberately intensive. Twenty-five individuals at elevated risk for PMADs will be recruited prior to conception and followed across six in-person timepoints spanning the menstrual cycle, pregnancy, and early postpartum, with additional remote follow-ups extending through the first postpartum year. Recruiting before conception is the design’s defining feature. Most perinatal brain studies begin during pregnancy, which means researchers never observe the pre-pregnancy baseline against which change should be measured. By anchoring each participant’s trajectory to her own preconception state, the team can distinguish pregnancy-induced neuroplasticity from individual differences that were present all along.

The neuroimaging protocol reads like a catalog of modern magnetic resonance techniques. Participants will undergo high-resolution structural MRI to quantify cortical and subcortical anatomy, along with functional brain mapping using multi-echo resting-state fMRI, a method that acquires multiple echo times simultaneously so that researchers can separate true neural signal from physiological and motion-related noise. Diffusion MRI will map the brain’s white matter microstructure by tracking the directional diffusion of water molecules along axonal bundles, while arterial spin labeling, or ASL, will measure cerebral blood flow without injecting any contrast agent, using magnetically labeled blood water as an endogenous tracer.

Perhaps the most technically ambitious elements target brain chemistry directly. The study will deploy ultra-high field MR-based techniques for measuring glutamate, including GluCEST, which stands for glutamate chemical exchange saturation transfer, and proton magnetic resonance spectroscopy. GluCEST exploits the chemical exchange properties of glutamate’s amine group to produce maps of glutamate concentration with far higher spatial resolution than conventional spectroscopy allows. Because glutamate is the brain’s principal excitatory neurotransmitter and a key player in synaptic plasticity, tracking its fluctuations across the menstrual cycle and pregnancy could reveal how hormonal surges reshape excitatory signaling in circuits implicated in mood regulation, including the dorsolateral prefrontal cortex.

Neuroimaging alone cannot capture psychiatric risk, so the project pairs its brain data with biofluid sampling and deep clinical phenotyping. Blood and other biofluids will be collected at each timepoint, enabling measurement of hormonal and inflammatory markers alongside complete blood counts. Structured clinical interviews will assess categorical diagnoses, while a battery of dimensional symptom measures captures the heterogeneity and transdiagnostic features of perinatal psychopathology. The assessment arsenal spans validated instruments for depression, anxiety, pregnancy-specific anxiety, sleep, emotion regulation, trauma history, and maternal attachment, including the Edinburgh Postnatal Depression Scale, the Patient Health Questionnaire-9, the Generalized Anxiety Disorder-7 scale, the Pregnancy-Related Anxiety Scale, and the Daily Record of Severity of Problems, which tracks premenstrual symptoms day by day.

That last instrument points to a second conceptual pillar: the menstrual cycle as a natural experiment in hormone sensitivity. Premenstrual dysphoric disorder, or PMDD, affects a subset of individuals who appear unusually sensitive to normal hormonal fluctuations, and a history of premenstrual mood symptoms is one of the strongest known predictors of perinatal depression. The PMADS project will characterize menstrual cycle-related brain changes before conception using the same imaging modalities applied during pregnancy, then test whether preconception network features and cycle-related brain dynamics predict subsequent perinatal symptom emergence. In effect, the study treats each participant’s response to her own hormonal cycles as a personalized probe of hormone sensitivity that can be compared against her response to the far larger hormonal excursion of pregnancy.

The analytical plan is equally forward-looking. Longitudinal analyses will model nonlinear trajectories of brain and symptom change across the perinatal period using generalized additive mixed models, a statistical framework flexible enough to capture the non-monotonic patterns that hormonal transitions often produce. The team will evaluate whether features of personalized functional networks, mapped before conception, forecast who develops symptoms, and whether the magnitude of pregnancy-induced neuroplasticity relates to psychiatric outcomes. Multiple-comparison control through false discovery rate procedures will guard against spurious findings in a dataset this rich, and the resulting resource is intended as a deeply phenotyped longitudinal dataset for investigating brain-behavior relationships across the perinatal period.

The clinical payoff could be substantial. Findings are expected to inform future larger-scale studies aimed at advancing mechanistic understanding of PMADs, improving individualized risk stratification, and supporting the development of personalized preventive and neuromodulatory interventions, including techniques such as transcranial magnetic stimulation. If preconception brain signatures or cycle-related hormone sensitivity turn out to predict perinatal illness, clinicians could one day identify high-risk individuals before pregnancy begins and intervene early, rather than waiting for symptoms to appear. The study, approved by the University of Pennsylvania’s Institutional Review Board and funded in part by the National Institutes of Health, represents a small cohort with outsized ambitions: to transform pregnancy from psychiatry’s blind spot into one of its most informative natural experiments.

Subject of Research: The PMADS project: a longitudinal multimodal cohort study to understand risk for perinatal mood and anxiety disorders

Article Title: The PMADS project: a longitudinal multimodal cohort study to understand risk for perinatal mood and anxiety disorders

Article References: Rubau-Apa, N., Hayes, C., Francisco, A., Rush, S., Rana, H., Islam, M., Hunter, L., Pritschet, L., Salo, T., Senapati, S., Hantsoo, L., Indrakanti, D., Beydler, E. M., Baller, E. B., Barzilay, R., Calkins, M. E., Cieslak, M., Detre, J. A., Dhaliwal, S., … Shanmugan, S. (2026). The PMADS project: a longitudinal multimodal cohort study to understand risk for perinatal mood and anxiety disorders. BMC Psychiatry. https://doi.org/10.1186/s12888-026-08519-7

Image Credits: AI Generated

DOI: 10.1186/s12888-026-08519-7

Keywords: PMADS, perinatal mood and anxiety disorders, neuroimaging, pregnancy, brain plasticity, glutamate, menstrual cycle, precision psychiatry, BMC Psychiatry, project, longitudinal, multimodal